<DOC>
	<DOCNO>NCT02494609</DOCNO>
	<brief_summary>A Two-way Study Evaluate Potential Pharmacokinetic Interactions Between Sotagliflozin ( LX4211 ) Oral Contraceptive Containing Norgestimate Ethinyl Estradiol , Healthy Premenopausal Women .</brief_summary>
	<brief_title>Oral Contraceptive DDI Study</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Premenopausal females body mass index ( BMI ) 18 32 kg/m2 ( inclusive ) Have receive oral contraceptive Screening period least 15 day prior first dose Period 1 History contraindication combine oral contraceptive tablet include thrombosis history thromboembolic disease , recurrent jaundice , acute chronic liver disease , hormonallyinduced migraine , undiagnosed vaginal bleeding , significant hyperlipidemia , mammary , endometrial , hepatic carcinoma ( know suspect ) Prior exposure sotagliflozin ( LX4211 ) History clinically relevant psychiatric , renal , hepatic , pancreatic , endocrine , cardiovascular , neurological , hematological , GI abnormality Concurrent condition could interfere safety and/or tolerability measurement Women breastfeed plan become pregnant study Positive serum pregnancy test Have take injectable contraceptive hormonal intrauterine device within 12 month prior first dose Period 1 topical control delivery contraceptive ( patch ) 3 month prior first dose Period 1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>